(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Outlook Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast OTLK's revenue for 2024 to be $18,608,413, with the lowest OTLK revenue forecast at $18,608,413, and the highest OTLK revenue forecast at $18,608,413. On average, 4 Wall Street analysts forecast OTLK's revenue for 2025 to be $183,585,655, with the lowest OTLK revenue forecast at $49,448,929, and the highest OTLK revenue forecast at $412,508,169.
In 2026, OTLK is forecast to generate $1,115,008,280 in revenue, with the lowest revenue forecast at $687,665,432 and the highest revenue forecast at $1,770,922,295.